11 results about "High risk populations" patented technology

The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.

The invention provides a Crohn disease early screening marker based on plasma proteomics. The early screening marker comprises the following nine proteins: CD274, CHI 3L1, REG1B, ITGAV, PRSS8, ITGA11, GDF15, DEFA1DEFA1B and IL6. The early screening marker provided by the invention can accurately and non-invasively predict CD as long as 16 years before diagnosis, which provides an important value for early screening of CD high risk groups and formulation of intervention measures. The invention also provides application of the Crohn disease early screening marker and an early screening kit for Crohn disease prediction.

The present invention belongs to the technical field of AIDS prevention and control, and specifically relates to a method for evaluating the effectiveness of intervention measures for high-risk populations of HIV transmission and its application. The effectiveness evaluation method includes the following steps: S1 constructing a prediction model for the risk of new infections; S2 based on the prediction model for the risk of new infections, constructing an effectiveness evaluation model for intervention measures for high-risk populations of HIV transmission, and the effectiveness evaluation model for intervention measures for high-risk populations of HIV transmission includes an effectiveness evaluation model for TasP intervention measures. The effectiveness of the TasP intervention measures is characterized by the proportion of the decrease in new infections after the TasP intervention measures are strengthened. The present invention constructs a prediction model for the risk of new infections to evaluate the impact of intervention measures for high-risk populations of HIV transmission in the real world on reducing new HIV infections in the MSM population. The evaluation results of the present invention provide theoretical guidance for optimizing intervention measures, formulating appropriate intervention strategies, and reasonably allocating health resources.

Disclosed herein are methods for detecting a false positive initial sample result in a subject initially identified as having, or at risk for, cancer. Such methods can be performed on a sample obtained from the subject while undergoing a colonoscopy. Thus, methods can be useful for confirming or contradicting the initial identification that the high risk subject is at risk for cancer. Altogether, such methods are valuable for improving precision of a cancer test.

The invention discloses a clinical decision support method for identifying smoke disease based on biomarkers in blood. The method comprises the following steps: firstly, determining differential genes between a smoke disease patient and a healthy control group by analyzing a data set in a GEO database; biological pathways and disease types enriched by the differential genes are further analyzed; then identifying a biomarker related to the smoke disease through LASSO and SVM-RFE machine learning algorithms, and evaluating the predictive ability of the biomarker through an ROC curve; finally, screening to obtain CFD and DKFZp434L192 genes, and constructing a nomogram based on the expression of the two genes in the data set so as to predict smoke disease high-risk population in general population. Clinical samples are further collected, expression of CFD and DKFZp434L192 genes in whole blood of smoke disease patients is verified through RT-qPCR, and the technical problem that at present, no efficient recognizable cause of smoke disease exists is solved. By analyzing the expression of the characteristic gene in the blood of the patient, the high-risk group of the smoke disease is quickly predicted, and decision support is provided for timely intervention and treatment.

The present invention discloses a preparation method and application of metalloproteinase-9 antigenic determinant-imprinted nanoparticles. The preparation method adopts the epitope imprinting method to design and synthesize the MMP-9 carboxyl-terminal nonapeptide YDILQCPED as the antigenic determinant template. Zinc acrylate and the green low-melting reagent choline chloride-MAA are used as functional monomers to prepare the imprinted nanoparticles. The polymerization factors that affect the adsorption performance of the imprinted nanoparticles are investigated, and MMP-9 imprinted nanoparticles with excellent adsorption effect, strong specificity, and high reproducibility are obtained. The prepared MIPs can be used as a new highly selective adsorption material for MMP-9 protein and have good application prospects for the enrichment, separation, and detection of trace cancer markers. They are of great significance in the early screening, early diagnosis, treatment guidance, prognosis assessment, and screening of high-risk populations of cancer patients.

Disclosed herein are methods for detecting a false positive initial sample result in a subject initially identified as having, or at risk for, cancer. Such methods can be performed on a sample obtained from the subject while undergoing a colonoscopy. Thus, methods can be useful for confirming or contradicting the initial identification that the high risk subject is at risk for cancer. Altogether, such methods are valuable for improving precision of a cancer test.

Disclosed herein are methods for detecting a false positive initial sample result in a subject initially identified as having, or at risk for, cancer. Such methods can be performed on a sample obtained from the subject while undergoing a colonoscopy. Thus, methods can be useful for confirming or contradicting the initial identification that the high risk subject is at risk for cancer. Altogether, such methods are valuable for improving precision of a cancer test.

The present invention discloses a blood metabolic marker set for diagnosing Alzheimer's disease and its screening method and application, belonging to the field of molecular detection technology. The present invention screens and verifies a set of specific and efficient AD blood metabolite sets, including 22 species, which makes up for the problems of low specificity and poor diagnostic accuracy of a single biomarker. The invention provides a set of metabolites with AD specificity, which has a good effect on the classification prediction of AD. At the same time, a metabolite feature selection method based on machine learning is proposed, and the identified set of metabolites is applied to the metabolic pathway level to explain the metabolic disorder of AD. It can provide a metabolic perspective explanation for the pathological mechanism of AD, and can conduct large-scale early screening for high-risk populations, which has clinical guidance significance.

The invention discloses application of specific macular morphological characteristics as a biomarker for early prediction of age-related macular degeneration. The specific macular morphological characteristics are as follows: under non-mydriasis natural light, the macular is divided into a central area, an inner ring and an outer ring, the inner ring and the outer ring are further divided into four directions of upper and lower nasal temple, and the specific macular morphological characteristics are shown on the upper parts of the thin inner ring and the outer ring, the thick central area and other outer ring parts. The invention reveals that specific macular morphological characteristics can be used as a biomarker for early prediction of age-related macular degeneration through a potential profile analysis method for the first time. According to comparison with a population macular thickness reference value, the high-risk population of senile macular degeneration is identified through the deviation value, and risk stratification and early intervention are promoted.